![](/fileadmin/_processed_/csm_Apeiron_Board_148036936f.png)
Ligand Pharma to acquire Apeiron Biologics
As part of the US100m acquisition, Ligand Pharmaceuticals Inc has committed to invest up to US$4m in invIOs Holding AG, Apeiron Biologics...
![](/fileadmin/_processed_/csm_tubulis_linker_ADC_web_bccd46dac0.jpg)
Tubulis from Munich doses first Patient with own ADC linker technology
Tubulis, based in Martinsried near Munich, announced today that the first patient has been treated in its first Phase 1/2a...
![](/fileadmin/_processed_/csm_capsule_by_design_exvolvo-web_5315d0b612.jpg)
No more needles - Exvolvo arises with help of Verily and NLC Health
NLC Health Ventures launches a new early-stage drug delivery company. The venture builder from The Netherlands partners with Verily from which Exolvo...
![](/fileadmin/_processed_/csm_Peter_Sondermann__c__Tacalyx_d5b3b6d2e0.jpg)
Tacalyx' extends seed capital financing
Tacalyx GmbH, the 2019 spin-out from Peter Seeberger's glycan research group, has doubled its seed funding from €7m to to a bit over €14m to advance...
![](/fileadmin/_processed_/csm_EBC_c_CDC_7b5c041c11.png)
Hornet Therapeutics reports first data of EBV-triggered disease blocker
Hornet Therapeutics Ltd that was spun out in 2020 from the group of Christoph Hess (now University Cambridge) at University Basel, has...
![](/fileadmin/_processed_/csm_NOVo_New_434e85ba4f.png)
Obesity: reseachers switch on brown fat cells
The new discovery could herald a revolution in obesity research. If the principle discovered in male mice also applies in humans, therapeutics...
![](/fileadmin/Content/NewsAndStories/2024/Bildschirmfoto_2024-07-09_um_09.31.12.png)
EMA-Gate: PharmaMar wins suit against EMA
The European Commission has corrected its decision C(2018) 4831 from 2018 not to grant marketing authorisation for Aplidin (plitidepsin), a peptidic...